Lonafarnib

Generic Name: Lonafarnib

Brand Names: Zokinvy

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₁Br_₂ClN_₄O_₂

CAS Number: 193275-84-2

Unique Ingredient Identifier: IOW153004F

Background: Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, a...

Indication: Lonafarnib is a farnesyltransferase inhibitor indicated in patients aged 12 months and older with a body surface area of at least 0.39 m to reduce the risk of mortality associated with Hutchinson-Gilford progeria syndrome (HGPS). It is also indicated in this same population for the treatment of processing-deficient progeroid laminopathies that either involve...

Associated Conditions: Death, Hutchinson-Gilford Progeria Syndrome, Processing-deficient Progeroid Laminopathies

Associated Therapies: -

Clinical Trials

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Phase 3

Active, not recruiting

Conditions: Hepatitis D, Chronic

Interventions: Drug: Lonafarnib
Drug: Ritonavir

First Posted Date: 2022-02-08

Last Posted Date: 2023-05-06

Lead Sponsor: Soroka University Medical Center

Target Recruit Count: 30

Registration Number: NCT05229991

Locations: 🇳🇿
New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
🇹🇷
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey, Istanbul, Turkey
🇮🇱
Soroka UMC, Be'er Sheva, Israel

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

Conditions: Progeria
HGPS

First Posted Date: 2019-03-29

Last Posted Date: 2021-04-15

Lead Sponsor: Eiger BioPharmaceuticals

Registration Number: NCT03895528

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Phase 3

Completed

Conditions: Hepatitis Delta Virus

Interventions: Drug: Lonafarnib
Drug: Placebo Lonafarnib
Drug: Ritonavir
Drug: Placebo Ritonavir
Drug: PEG IFN-alfa-2a

First Posted Date: 2018-10-25

Last Posted Date: 2023-04-14

Lead Sponsor: Eiger BioPharmaceuticals

Target Recruit Count: 407

Registration Number: NCT03719313

Locations: 🇺🇸
University of Miami Schiff Center for Liver Disease, Miami, Florida, United States
🇮🇹
Azienda Ospedaliero Universitaria di Parma, Parma, Italy
🇮🇹
Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy

and more 113 locations

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Phase 2

Completed

Conditions: Liver Disease
Hepatitis D

Interventions: Drug: Peg-interferon lambda
Drug: Lonafarnib
Drug: Ritonavir

First Posted Date: 2018-07-26

Last Posted Date: 2021-12-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 26

Registration Number: NCT03600714

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Phase 2

Withdrawn

Conditions: Chronic Delta Hepatitis

Interventions: Drug: Lonafarnib
Drug: Ritonavir

First Posted Date: 2016-11-18

Last Posted Date: 2021-02-16

Lead Sponsor: Eiger BioPharmaceuticals

Registration Number: NCT02968641

Titrating-Dose of Lonafarnib in Combination With Ritonavir

Phase 2

Completed

Conditions: Chronic Delta Hepatitis

Interventions: Drug: lonafarnib
Drug: Ritonavir

First Posted Date: 2015-08-19

Last Posted Date: 2023-06-22

Lead Sponsor: Eiger BioPharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02527707

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Phase 2

Completed

Conditions: Hepatitis D

Interventions: Drug: Lonafarnib
Drug: Ritonavir
Other: Placebo

First Posted Date: 2015-07-30

Last Posted Date: 2018-09-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 22

Registration Number: NCT02511431

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Phase 2

Completed

Conditions: Chronic Hepatitis D Infection

Interventions: Drug: lonafarnib
Drug: ritonavir
Drug: Pegylated interferon-alfa-2a

First Posted Date: 2015-04-30

Last Posted Date: 2023-03-03

Lead Sponsor: Eiger BioPharmaceuticals

Target Recruit Count: 55

Registration Number: NCT02430194

Locations: 🇹🇷
Ankara University Medical School, Ankara, Turkey

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Phase 2

Completed

Conditions: Chronic Hepatitis D Infection

Interventions: Drug: lonafarnib
Drug: peginterferon alfa-2a
Drug: ritonavir

First Posted Date: 2015-04-30

Last Posted Date: 2022-11-29

Lead Sponsor: Eiger BioPharmaceuticals

Target Recruit Count: 21

Registration Number: NCT02430181

Locations: 🇹🇷
Ankara University Medical School, Ankara, Turkey

Lonafarnib for Chronic Hepatitis D

Phase 2

Completed

Conditions: Hepatitis D

Interventions: Other: Placebo
Drug: Lonafarnib

First Posted Date: 2011-12-20

Last Posted Date: 2016-08-31

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 14

Registration Number: NCT01495585

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy